Natera Inc.
(NASDAQ:NTRA) stock is up Tuesday as the company celebrates a significant milestone with the National Comprehensive Cancer Network (NCCN) recognizing its Signatera technology for muscle-invasive bladder cancer.
The recognition marks the third NCCN guideline recommendation for circulating tumor DNA (ctDNA) testing, which could enhance treatment protocols for patients, reflecting positively on Natera's market position and growth potential.
Read Also: Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst NCCN Signatera Guideline Update The NCCN has updated its Clinical Practice Guidelines to include Signatera-guided adjuvant treatment for muscle-invasive bladder cancer, highlighting the importance of ctDNA testing in clinical decision-making.
The update is supported by evidence from the IMvigor011 trial, which demonstrated the effectiveness of Signatera in guiding treatment decisions post-surgery.
